ametantrone (HAQ)

RN given refers to parent cpd; structure

Also Known As:

HAQ; 1,4-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-9,10-anthracenedione diacetate; NSC 196473; NSC 287513; NSC-196473; NSC-287513; ametantrone diacetate; ametantrone ion (1-); 1,4-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-9,10-anthracenedione

Networked: 1764 relevant articles (164 outcomes, 192 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Strand, Vibeke: 37 articles (01/2022 - 04/2005)
2.	Michaud, Kaleb: 19 articles (06/2022 - 10/2004)
3.	Pincus, Theodore: 18 articles (09/2019 - 10/2004)
4.	Gladman, Dafna D: 17 articles (07/2022 - 03/2007)
5.	Combe, Bernard: 15 articles (11/2022 - 11/2003)
6.	Khanna, Dinesh: 15 articles (01/2017 - 05/2005)
7.	Gossec, Laure: 14 articles (07/2022 - 07/2010)
8.	Bodur, Hatice: 14 articles (04/2022 - 06/2011)
9.	Furst, Daniel E: 14 articles (04/2022 - 09/2002)
10.	Mease, Philip J: 13 articles (07/2022 - 01/2008)

Related Diseases

1.	Pain (Aches) 08/25/2023 - "The pain-VAS and J-HAQ highly contributed to WPAI in patients with RA in clinical remission." 09/01/2005 - "A significant decrease was recorded in different ACR response components, including the tender joint and swollen joint counts, pain score and patient and physician global disease assessments, as well as the DAS28 index; most of them improved after week 5. ESR and CRP, but not the HAQ score, had decreased significantly at week 20. " 07/01/2012 - "At Week 25, mean changes from baseline in PtGA, pain, HAQ-DI, and PCS scores were statistically significant and exceeded minimum clinically important differences (MCID) in the biweekly treatment group, compared with little to no improvement in placebo group. " 11/01/1995 - "There was marked improvement in all clinical stores at 24 h including a decrease in pain score (p < 0.0005), stiffness (p < 0.00005), joint tenderness score and modified Health Assessment Questionnaire (HAQ) (p < 0.005), and an increase in well being (p < 0.001). " 01/01/2022 - "At week 12, UPA- vs ABA-treated patients had significantly greater improvements in PtGA, pain, HAQ-DI, morning stiffness severity, EQ-5D-5L, 2/4 WPAI domains, and 3/8 SF-36 domains and Physical Component Summary (PCS) scores (P<0.05); significant differences persisted at week 24 for HAQ-DI, morning stiffness severity, SF-36 PCS and bodily pain domain, and WPAI activity impairment domain. "
2.	Fatigue 10/27/2023 - "When compared to baseline, FACIT-Fatigue, HAQ-DI, and VAS scores were significantly improved without increasing markers of muscle damage. " 03/01/2018 - "Baseline remissions by all criteria significantly improved HAQ, Euroqol, SF36 and fatigue scores compared with low disease activity (LDAS); AUCs showed significant benefits for all HRQoLs persisted over 12-months. " 01/01/2017 - "In AMBITION, TCZ-treated patients reported significantly greater mean improvements in HAQ (-0.7 vs -0.5), FACIT-Fatigue (8.7 vs 5.7), SF-36 PCS (9.8 vs 7.8) and five SF-36 domains at week 24 than with MTX; 45.0%-84.0% of TCZ-treated patients reported improvements ≥MCID, and 24.3%-52.1% reported scores ≥normative values across all PROs versus 39.4%-81.8% and 14.5%-45.0%, respectively, with MTX. " 09/01/2015 - "In these long-standing RA patients, fatigue levels were high and mainly explained by HAQ and psychological distress but improved with treatment indicating a link with disease activity. " 03/01/2013 - "In particular, a significant improvement in function and fatigue indices (HAQ and FACIT) was found since T1 to T4 as compared to T0. "
3.	Rheumatoid Arthritis 04/01/2004 - "Scoring poorly on the health assessment questionnaire (HAQ) has recently been shown to be a strong predictor of morbidity and mortality in rheumatoid arthritis (RA), while a good HAQ score is predictive of a better outcome. " 12/01/2017 - "HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis: methodological issues." 12/01/2017 - "In reply to the letter to the Editor, "HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis"." 12/01/2017 - "HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis." 08/11/2015 - "To investigate the course of functional status assessed by health assessment questionnaire (HAQ) in rheumatoid arthritis (RA) patients with sustained clinical remission (REM). "
4.	Rheumatic Diseases (Rheumatism) 01/01/2017 - "Univariable logistic regression analysis of potential baseline predictors of European League Against Rheumatism (EULAR) good clinical response, EULAR good/moderate response, 28-joint Disease Activity Score with three variables including the erythrocyte sedimentation rate (DAS28-3V-ESR) remission and Health Assessment Questionnaire (HAQ) response were performed. " 01/01/2010 - "The main outcome measurements included the Health Assessment Questionnaire (HAQ), the Larsen score, and clinical remission according to the American Rheumatism Association (ARA) criteria. " 12/01/2010 - "Treatment effects were estimated using four outcome measures from the included studies: European League Against Rheumatism (EULAR) and ACR20 response rates and mean improvement in disease activity score-28 (DAS-20) and HAQ. " 01/01/2017 - "Regarding clinical results (DAS28-ESR, Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI) low disease activity and remission; ACR20/50/70 and European League Against Rheumatism (EULAR) response; Health Assessment Questionnaire Disability Index (HAQ-DI) score), no relevant differences between monotherapy and combination patients were observed at 1 year. " 01/01/2015 - "The effectiveness of treatment was assessed using the 28-joint Disease Activity Score (DAS28), the Health Assessment Questionnaire (HAQ), measures of remission, the European League Against Rheumatism (EULAR) response during 0-6 months from start of treatment, and survival-on-drug during the first 30 months. "
5.	Psoriasis (Pustulosis Palmaris et Plantaris) 07/01/2012 - "A significant improvement of the clinical scores was found at follow-up with respect to the baseline: HAQ modified for SpA (HAQ-S) (P = 0.0001); Psoriasis Area and Severity Index (P = 0.0001) and Nail Psoriasis Severity Index (P = 0.35). " 01/01/2022 - "Efficacy outcomes included achievement of ACR responses, Psoriasis Area and Severity Index responses, minimal disease activity and change from baseline and clinically meaningful improvement in the HAQ Disability Index. " 01/01/2023 - "Secondary endpoints (through M6) included: ACR20/50/70 response; change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI); ≥75% improvement in Psoriasis Area and Severity Index (PASI75) response, and enthesitis and dactylitis resolution. " 06/01/2014 - "Secondary endpoints included week 24 Health Assessment Questionnaire-Disability Index (HAQ-DI) improvement, ACR50, ACR70 and ≥75% improvement in Psoriasis Area and Severity Index (PASI75). " 01/01/2020 - "Model input parameters (Psoriasis Area Severity Index, Health Assessment Questionnaire (HAQ), withdrawal rates, costs, and resource use) were collected from clinical trials, published literature, and official reports. "

Related Drugs and Biologics

1.	amsonic acid (DAS)
2.	Prostaglandins A
3.	C-Reactive Protein
4.	Antirheumatic Agents (DMARD)
5.	Adalimumab (Humira)
6.	Infliximab (Remicade)
7.	Methotrexate (Mexate)
8.	tofacitinib
9.	1- hydroxy- 5,8- bis(2- ((2- hydroxyethyl)amino)ethylamino)- 9,10- anthracenedione
10.	Abatacept (Orencia)

Related Therapies and Procedures

1.	Therapeutics
2.	Ambulatory Care (Outpatient Care)
3.	Mud Therapy (Mud Bath)
4.	Time-to-Treatment
5.	Biological Therapy